Literature DB >> 30952754

Estimating Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Whole-brain Radiotherapy With a New Tool.

Heinke C Hansen1, Stefan Janssen1,2, Steven E Schild3, Dirk Rades4.   

Abstract

BACKGROUND/AIM: A new tool for estimating survival of patients receiving whole-brain radiotherapy (WBRT) for intracerebral metastases from renal cell carcinoma (RCC) was created. PATIENTS AND METHODS: The new WBRT-30-RCC was developed in 34 patients homogeneously treated with 30 Gy in 10 fractions of WBRT and compared to updated diagnosis-specific graded prognostic assessment DS-GPA and Dziggel score for predicting death within 6 months and survival for at least 6 months following WBRT.
RESULTS: WBRT-30-RCC included three groups with 6-month survival rates of 6.7% for those with 8-10 points, 38.5% for those with 12-14 points and 66.7% for those with 16-18 points. Positive predictive values (PPV)s for predicting death within 6 months were 93.3% using WBRT-30-RCC, 77.3% using updated DS-GPA and 93.7% using the Dziggel score. PPVs for predicting survival for at least 6 months were 66.7%, 50.0% and 50.0%, respectively.
CONCLUSION: WBRT-30-RCC was more precise than the other scores in predicting survival for at least 6 months, although all three scores were not optimal. For predicting death within 6 months, WBRT-30-RCC and Dziggel score were similarly accurate and superior to the updated DS-GPA. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Renal cell carcinoma; diagnosis-specific scoring tool; metastatic disease; survival prognosis; whole-brain radiotherapy

Mesh:

Year:  2019        PMID: 30952754     DOI: 10.21873/anticanres.13321

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Estimating the Lifespan of Elderly Patients With Cerebral Metastases from Kidney Cancer.

Authors:  Dirk Rades; Trang Nguyen; Steven E Schild
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.